There is level 1 evidence supporting the value of zolendronic acid (Zometa, Novartis) as an adjuvant treatment for premenopausal women with endocrine-responsive breast cancer, researchers reported here at the 34th Annual San Antonio Breast Cancer Symposium. That means that a prospective clinical trial has met its end points, so the studied agent qualifies for use in standard clinical practice, said presenter James Ingle, MD, from the Mayo Clinic in Rochester, Minnesota.

Medscape,  by Nick Mulcahy, 12/12/2011

Tags: Cancer